Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +45.00p +2.05% 2,237.50p 2,230.00p 2,245.00p 2,237.50p 2,200.00p 2,210.00p 40,527.00 16:12:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 120.9 -7.2 -43.4 - 1,358.24

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
02/12/201610:52(Chi-Med)Hutchinson China Meditech Limited855.00
28/11/201211:00Hutchison China Meditech- CHARTS AND DISCUSSION69.00

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 2,192.50p.
Hutchison China Meditech has a 4 week average price of 1,930.38p and a 12 week average price of 1,864.50p.
The 1 year high share price is 2,907.50p while the 1 year low share price is currently 1,625p.
There are currently 60,703,323 shares in issue and the average daily traded volume is 13,546 shares. The market capitalisation of Hutchison China Meditech is £1,358,236,852.13.
steeplejack: Written up in latest IC -In our view, the high potential of the clinical pipeline makes Chi-Med a very attractive investment proposition and recent share price weakness offers an excellent entry point. Plus, as the group closes in on commercial launch it is likely to grab the attention of more biotech-savvy US investors and that could drive the price up further. Buy.Investors Chronicle 2 Dec
miti 1000: Very good news this morning though you would never guess it from the share price.
steeplejack: Hopefully that will be the case and the healthcare sector is a bit perkier of late.That said,I find it hard to dismiss the idea that we ,the U.K. holders,got well and truly stuffed by an unexpectedly large placing discount in the USA.We also have to contend with the vagaries of currency moves.Future financing will almost certainly be concentrated in the States.Moreover,it's worth remembering that there's no bid possibility here,this is effectively a close company. The price is a third off its highs.I occasionally consider just kicking the stock into the long grass because it's going to be a long time before the stock hits any new highs.No bid,no yield,it could be heavy going even with reasonable trading updates.When they did that US placing,they behaved like a company majority owned by Hutchinson,they didn't give a fig for existing UK shareholders.The past is the past,it's the future share price I'm interested in.
steeplejack: I think that explains the sharp drop in share price some weeks back.The intended pricing of the ADSs must of leaked out.An equivalent London price of £19.42 is a sizeable discount to the existing AIM price.I'd be surprised if we didn't see a few taking a quick profit in the US.Maybe,it was optimistic but I thought (especially given you can get a slug of stock)they might get this placing away at nearer the AIM price ie £22-50 odd.Not to be.I can see them doing the greenshoe,additional placing,in full.Who the hell wouldn't want to go for that at a discount to the London price of getting on for 15%!Nonetheless,they've done the issue in a difficult environment and have a listing in the US which will no doubt prove to be the primary vehicle for any intended fund raising in future years (as it has proven for GWP). "7,500,000 ADSs were sold in the Offering at a price of US$13.50 per ADS, and the offering price is thus equivalent to approximately GBP19.42 per ordinary share (on the basis of an assumed exchange rate as quoted in the preliminary prospectus of GBP1.00 to US$1.39). Each ADS represents one-half of one ordinary share of Chi-Med. The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on March 17, 2016 under the ticker symbol "HCM." Chi-Med's ordinary shares will continue to be traded on the AIM market of the London Stock Exchange following the Offering under the ticker symbol "HCM."
hamsterdam: Do us existing shareholders in anyway benefit from the Nasdaq listing? Apart from any rise in the share price on AIM?
nerdofsteel: Not being proposed at the moment but I hope that is what eventually happens. It would hit the share price only in that we would end up with a huge valuation on NASDAQ. Eventually I think the Innovation platform (drugs research and development arm) will become a completely separate NASDAQ Company, worth many multiples of what it is today.
hamsterdam: Any likelihood HCM decide to delist from the AIM and focus on Nasdaq only? That's my biggest worry as it may hit the share price hard.
nerdofsteel: We could via a U.S. Broker, but this will be heavily marketed to Instititional Investors and I think the Company will be pleasantly surprised by the amount of cash that is raised. Smart move, unlimited offer, could raise A LOT of $. The Chairman recently outlined a nice example of a drug calledIbrutinib, developed by Abbvie/Pharmacyclics. That drug alone added $40M to the market cap of Pharmacyclics over a 6 year period before they were acquired by AbbVie. His point is this. Leading Oncology drugs with high efficiacy are worth billions. We have several leading candidates which have taken hundreds of millions of dollars to develop. The only negative I can see is if Clinton wins the election as she is desperate to cap drug prices. The problem for cancer patients is companies will cut back on development of new drugs as a result, as they may not get a return on their investment. Clinton could potentially then effectively be responsible for patients deaths, especially those with rarer forms of cancer. Let's hope we raise a lot of $ on NASDAQ. I also hope we eventually spin off the Innovation Platform into a separate NASDAQ only Company, worth tens of billions of dollars. That will provide a huge reward for those willing to keep this as a long term hold. I'm here for the next 10 years and will look forward to looking back when today's share price will seem very small!
protean: A few buyers tempted in today as 800p continues to hold as support on the chart. Just reading the finals again the tone is very bullish indeed, full of confidence for the future. --- "Continued very considerable growth potential." "Chi-Med has had a highly successful 2013. We have propelled our revenues and profit, and the drivers of this success are set to continue." "Our China Healthcare Division continues to grow rapidly" "We expect 2014 to be a breakout year for our Drug R&D Division" "The opportunities facing us are very considerable and we believe we will deliver further substantial shareholder value this year and beyond." -- The share price certainly reacted very favourably running up from 700p or so on Feb 18th to just under 1000p a few weeks later. Inevitably profit taking set in after such a sharp rise and the price has drifted back about 20% since then. With the bullish story still the same but the shares on offer at a much better price, now looks to be a decent entry point on the chart at 825p offered.
protean: hTTp:// "he is predicting further significant rises in other stocks, such as the new top holding in the fund, Hutchison China Meditech, which he thinks is "absurdly undervalued"." "The manager also tipped Hutchison China Meditech – now Mr Slater's top holding at 7.3 per cent – whose share price he said was "completely wrong" and failed to reflect the company's potential."
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161203 23:47:14